title: Therapeutic effect of MIP-1alpha-recruited dendritic cells on preestablished solid and metastatic tumors.
abstract: We previously found that dendritic cell (DC) precursors could be recruited into the peripheral blood of B6 mice by administration of macrophage inflammatory protein (MIP)-1alpha. These MIP-1alpha-recruited DCs could induce anti-tumor protective immunity when pulsed with tumor cell lysate. In this study, MIP-1alpha-recruited DCs could not effectively suppress preestablished tumor when pulsed with B16 tumor cell lysate. However, inoculation with these DCs expressing MAGE-1 induced an anti-tumor immunity against preestablished solid and metastatic tumor from B16-MAGE-1 cells. These MIP-1alpha-recruited DCs expressed higher level of CCR7 and displayed a more significant chemotactic response toward secondary lymphoid tissue. Therefore, they are superior in the induction of cytotoxic T lymphocytes and the inhibition of tumor development and metastasis than bone marrow-derived DCs. This study established a novel approach to the treatment of preestablished solid and metastatic tumors using MIP-1alpha-recruited DCs transduced with tumor antigen gene.
authors.affiliation: Shanghai Institute of Immunology, Institutes of Medical Sciences, Shanghai Jiao Tong University School of Medicine and Key Laboratory of Stem Cell Biology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences & SJTUSM, Shanghai, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Cao
authors.forename: Yanliang
authors.initials: Y
authors.lastname: Jin
authors.forename: Min
authors.initials: M
authors.lastname: Jin
authors.forename: Shan
authors.initials: S
authors.lastname: He
authors.forename: Qiaoli
authors.initials: Q
authors.lastname: Gu
authors.forename: Songbing
authors.initials: S
authors.lastname: He
authors.forename: Yuhua
authors.initials: Y
authors.lastname: Qiu
authors.forename: Hailiang
authors.initials: H
authors.lastname: Ge
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yoneyama
authors.forename: Yanyun
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D054405:Chemokine CCL3 / Q000494:pharmacology*; D002633:Chemotaxis; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy; D008213:Lymphocyte Activation; D008546:Melanoma, Experimental / Q000276:immunology* / Q000517:prevention & control / Q000556:secondary / Q000628:therapy*; D058950:Melanoma-Specific Antigens; D051379:Mice; D008810:Mice, Inbred C57BL; D009363:Neoplasm Proteins / Q000235:genetics; D054400:Receptors, CCR7 / Q000378:metabolism; D011994:Recombinant Proteins / Q000494:pharmacology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014161:Transduction, Genetic
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; C515371:Ccr7 protein, mouse; D054405:Chemokine CCL3; C072011:MAGEA1 protein, human; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D054400:Receptors, CCR7; D011994:Recombinant Proteins